Some Traders See Unusual Bullish Options Activity in Pfizer Inc.

 Some Traders See Unusual Bullish Options Activity in Pfizer Inc.

In today’s session Pfizer Inc. (PFE) registered an unusually high (300) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the January, 2017 call, expecting serious PFE increase. With 300 contracts traded and 22664 open interest for the Jan, 17 contract, it seems this is a quite bullish bet. The option with symbol: PFE170120C00028000 closed last at: $3.65 or 1.4% up. About 9.15 million shares traded hands. Pfizer Inc. (NYSE:PFE) has declined 4.58% since April 25, 2016 and is downtrending. It has underperformed by 10.59% the S&P500.

Analysts await Pfizer Inc. (NYSE:PFE) to report earnings on February, 7. They expect $0.50 EPS, down 5.66% or $0.03 from last year’s $0.53 per share. PFE’s profit will be $3.06B for 15.78 P/E if the $0.50 EPS becomes a reality. After $0.61 actual EPS reported by Pfizer Inc. for the previous quarter, Wall Street now forecasts -18.03% negative EPS growth.

Pfizer Inc. (NYSE:PFE) Ratings Coverage

Out of 18 analysts covering Pfizer (NYSE:PFE), 7 rate it a “Buy”, 0 “Sell”, while 11 “Hold”. This means 39% are positive. Pfizer has been the topic of 38 analyst reports since July 29, 2015 according to StockzIntelligence Inc. The rating was maintained by Leerink Swann on Monday, May 2 with “Market Perform”. The rating was reinitiated by JP Morgan on Thursday, April 7 with “Overweight”. Piper Jaffray maintained Pfizer Inc. (NYSE:PFE) on Saturday, September 5 with “Overweight” rating. The rating was maintained by Piper Jaffray on Friday, August 28 with “Overweight”. The rating was upgraded by SunTrust to “Neutral” on Wednesday, November 25. The stock has “Buy” rating given by Jefferies on Tuesday, September 13. The company was downgraded on Wednesday, November 2 by BMO Capital Markets. The firm earned “Buy” rating on Thursday, August 4 by Jefferies. As per Tuesday, June 14, the company rating was maintained by Jefferies. The rating was maintained by Jefferies on Monday, June 20 with “Buy”.

According to Zacks Investment Research, “Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company’s diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer healthcare products. Pfizer’s Animal Health business unit discovers, develops and sells products for the prevention and treatment of diseases in livestock and companion animals. It sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, veterinarians, livestock producers, and grocery and convenience stores. Pfizer Inc. is headquartered in New York.”

Insitutional Activity: The institutional sentiment increased to 1.18 in 2016 Q2. Its up 0.15, from 1.03 in 2016Q1. The ratio improved, as 80 funds sold all Pfizer Inc. shares owned while 704 reduced positions. 127 funds bought stakes while 678 increased positions. They now own 4.15 billion shares or 5.76% less from 4.40 billion shares in 2016Q1.
Moreover, Arvest Retail Bank Tru Division has 1.42% invested in Pfizer Inc. (NYSE:PFE) for 470,214 shares. Windsor Capital Management Llc holds 0.23% or 11,189 shares in its portfolio. Cambridge Inv Advisors Inc last reported 0.51% of its portfolio in the stock. Moreover, Analytic Ltd Liability Company has 0.13% invested in Pfizer Inc. (NYSE:PFE) for 317,002 shares. Headinvest Ltd Llc holds 0.37% or 27,566 shares in its portfolio. Finance & Mngmt Group Inc holds 0.09% of its portfolio in Pfizer Inc. (NYSE:PFE) for 8,280 shares. Kemnay Advisory Serv has 0.04% invested in the company for 1,500 shares. Heritage Wealth last reported 16,548 shares in the company. Parametric Risk Limited Liability holds 99,589 shares or 0.23% of its portfolio. Reik & Limited Liability, a New York-based fund reported 15,005 shares. Denver Advsr Ltd Limited Liability Company holds 0.75% or 471,943 shares in its portfolio. Legacy Private holds 66,182 shares or 0.34% of its portfolio. Roanoke Asset Management Ny last reported 0.13% of its portfolio in the stock. The Virginia-based Flippin Bruce And Porter has invested 2.83% in Pfizer Inc. (NYSE:PFE). Horan Cap Advisors Lc holds 0.24% of its portfolio in Pfizer Inc. (NYSE:PFE) for 8,437 shares.

Insider Transactions: Since November 4, 2016, the stock had 0 buys, and 2 sales for $882,530 net activity. $330,000 worth of Pfizer Inc. (NYSE:PFE) was sold by MADDALUNA ANTHONY J. On Friday, November 4 the insider BOURLA ALBERT sold $552,530.

Pfizer Inc. is a research-based global biopharmaceutical company. The company has a market cap of $193.16 billion. The Firm is engaged in discovering, developing and manufacturing of healthcare products. It has a 31.51 P/E ratio. The Company’s divisions include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

PFE Company Profile

Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research global biopharmaceutical company. The Firm is engaged in discovering, developing and manufacturing of healthcare products. The Company’s divisions include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The Company’s portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. The Company’s biopharmaceutical products include Lipitor, Sutent and the Premarin family of products. The Company’s biotechnology products include BeneFIX, ReFacto and Xyntha.

More recent Pfizer Inc. (NYSE:PFE) news were published by: which released: “Pfizer Ends Cholesterol Drug Trials as Earnings Fall Short” on November 01, 2016. Also published the news titled: “Better Buy: Gilead Sciences Inc. vs. Pfizer Inc.” on November 09, 2016.‘s news article titled: “Is Pfizer Inc.’s 6.4% Drop in October the Beginning of a Long Downtrend?” with publication date: November 07, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment